Literature DB >> 9618172

Reconstitution of wild-type or mutant telomerase activity in telomerase-negative immortal human cells.

J Wen1, Y S Cong, S Bacchetti.   

Abstract

Telomere shortening in human somatic cells and telomere maintenance in most human immortal cell lines and tumours correlate respectively with the absence and presence of telomerase, the enzyme that synthesizes telomeric DNA de novo . However, approximately 30% of in vitro immortalized human cell lines do not express this enzyme and maintain telomeres by an alternative pathway (ALT) that may also operate in some tumours. Human telomerase is a reverse transcriptase comprising minimally an RNA subunit (hTER) and a catalytic protein moiety (hTERT). Normal somatic cells retain expression of hTER but not of hTERT, and can be converted to a telomerase-positive phenotype by ectopic expression of the catalytic protein. We similarly have restored enzymatic activity to those ALT cell lines that retain hTER expression. We also report that in those ALT cells that are hTER negative, reintroduction of both hTER and hTERT is necessary and sufficient for conversion to telomerase positivity. Moreover, transfection of these cells with hTERT in conjunction with hTERs with a mutated template results in the expression of an enzyme with altered specificity. Reconstitution of telomerase activity in ALT cells, particularly an activity capable of synthesizing mutant telomeric DNA, may be exploited for the study of the ALT mechanism and its interaction with the telomerase-dependent pathway, and for assessing the effects of mutant telomeres on cell viability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618172     DOI: 10.1093/hmg/7.7.1137

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  Two inactive fragments of the integral RNA cooperate to assemble active telomerase with the human protein catalytic subunit (hTERT) in vitro.

Authors:  V M Tesmer; L P Ford; S E Holt; B C Frank; X Yi; D L Aisner; M Ouellette; J W Shay; W E Wright
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

3.  Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells.

Authors:  K Perrem; L M Colgin; A A Neumann; T R Yeager; R R Reddel
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

4.  Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes.

Authors:  K Liu; M M Schoonmaker; B L Levine; C H June; R J Hodes; N P Weng
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Heterogeneous nuclear ribonucleoproteins C1 and C2 associate with the RNA component of human telomerase.

Authors:  L P Ford; J M Suh; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells.

Authors:  C C Yu; S C Lo; T C Wang
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 7.  Human telomerase and its regulation.

Authors:  Yu-Sheng Cong; Woodring E Wright; Jerry W Shay
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

8.  Telomerase expression in chickens: constitutive activity in somatic tissues and down-regulation in culture.

Authors:  R N Venkatesan; C Price
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo.

Authors:  Y Jeffrey Chiang; Michael T Hemann; Karen S Hathcock; Lino Tessarollo; Lionel Feigenbaum; William C Hahn; Richard J Hodes
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 10.  Alterations in the Smad pathway in human cancers.

Authors:  Debangshu Samanta; Pran K Datta
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.